Human prostate cancer risk factors

被引:442
作者
Bostwick, DG
Burke, HB
Djakiew, D
Euling, S
Ho, SM
Landolph, J
Morrison, H
Sonawane, B
Shifflett, T
Waters, DJ
Timms, B
机构
[1] Bostwick Labs, Richmond, VA 23294 USA
[2] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA
[3] George Washington Univ, Dept Med, Washington, DC USA
[4] Georgetown Univ, Dept Cell Biol, Washington, DC USA
[5] US EPA, Natl Ctr Environm Assessment, Washington, DC USA
[6] Univ Massachusetts, Sch Med, Div Urol, Dept Surg, Worcester, MA USA
[7] Keck Sch Med, Canc Res Lab, Los Angeles, CA USA
[8] Lab Ctr Dis Control, Ottawa, ON K1A 0L2, Canada
[9] Radford Univ, Dept English, Radford, VA USA
[10] Purdue Univ, Dept Vet Clin Sci, W Lafayette, IN 47907 USA
[11] Gerald P Murphy Canc Fdn, Seattle, WA USA
[12] Univ S Dakota, Sch Med, Dept Anat, Vermillion, SD USA
关键词
prostate cancer; risk; diet; genetics; environment; epidemiology; animal models; cell culture; pathology; prostatic neoplasms;
D O I
10.1002/cncr.20408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature-based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies. (C) 2004 American Cancer Society.
引用
收藏
页码:2371 / 2490
页数:120
相关论文
共 1692 条
  • [1] Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer
    Aaltomaa, S
    Lipponen, P
    Vesalainen, S
    AlaOpas, M
    Eskelinen, M
    Syrjanen, K
    [J]. EUROPEAN UROLOGY, 1997, 32 (04) : 410 - 415
  • [2] Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer
    Aaltomaa, S
    Lipponen, P
    Ala-Opas, M
    Kosma, VM
    [J]. EUROPEAN UROLOGY, 2001, 39 (02) : 138 - 144
  • [3] Abdalla I, 1998, Semin Urol Oncol, V16, P207
  • [4] Impaired prostate tumorigenesis in Egr1-deficient mice
    Abdulkadir, SA
    Qu, ZC
    Garabedian, E
    Song, SK
    Peters, TJ
    Svaren, J
    Carbone, JM
    Naughton, CK
    Catalona, WJ
    Ackerman, JJH
    Gordon, JI
    Humphrey, PA
    Milbrandt, J
    [J]. NATURE MEDICINE, 2001, 7 (01) : 101 - 107
  • [5] ABRAHAMSSON PA, 1990, ANDROLOGIA, V22, P122
  • [6] THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER
    ABRAHAMSSON, PA
    FALKMER, S
    FALT, K
    GRIMELIUS, L
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) : 373 - 380
  • [7] ACHBAROU A, 1994, CANCER RES, V54, P2372
  • [8] ALCOHOLISM AND CANCER RISK - A POPULATION-BASED COHORT STUDY
    ADAMI, HO
    MCLAUGHLIN, JK
    HSING, AW
    WOLK, A
    EKBOM, A
    HOLMBERG, L
    PERSSON, I
    [J]. CANCER CAUSES & CONTROL, 1992, 3 (05) : 419 - 425
  • [9] PROCOAGULANT ACTIVITY MAY BE A MARKER OF THE MALIGNANT PHENOTYPE IN EXPERIMENTAL PROSTATE-CANCER
    ADAMSON, AS
    LUCKERT, P
    POLLARD, M
    SNELL, ME
    AMIRKHOSRAVI, M
    FRANCIS, JL
    [J]. BRITISH JOURNAL OF CANCER, 1994, 69 (02) : 286 - 290
  • [10] Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail
    Adedoyin, A
    Frye, RF
    Mauro, K
    Branch, RA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (03) : 215 - 219